We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene Therapy Prevents Seizures in Rat Model of Epilepsy

By Biotechdaily staff writers
Posted on 01 Dec 2006
Neurologists working with a rat model have used gene therapy to prevent the development of epileptic seizures after brain injury.

Investigators at the Children's Hospital of Philadelphia (PA, USA) employed an adeno-associated virus vector to insert the alpha-4 subunit gene (GABRA4) promoter into the brains of rats. More...
This gene therapy was intended to stimulate the production of GABAA receptor alpha-1 subunits in the hippocampal dentate gyrus region of the animals' brains. Previous studies had demonstrated reduced expression of GABR alpha-1 subunits and increased expression of alpha-4 subunits in dentate gyrus of epileptic rats compared with controls.

After successful acclimation of the transplanted gene, the rats were injected with pilocarpine, a drug that caused the animals to experience an epileptic seizure (status epilepticus or SE). Results published in the November 1, 2006, issue of the Journal of Neuroscience revealed that enhanced alpha-1 expression in the dentate gyrus resulted in a threefold increase in mean seizure-free time after SE and a 60% decrease in the number of rats developing epilepsy (recurrent spontaneous seizures) in the first four weeks after SE.

"We have shown that there is a window to intervene after a brain insult to reduce the risk that epilepsy will develop,” explained senior author Dr. Amy R. Brooks-Kayal, associate professor of pediatric neurology at the Children's Hospital of Philadelphia. "This provides a proof of concept that altering specific signaling pathways in nerve cells after a brain insult or injury could provide a scientific basis for treating patients to prevent epilepsy. This study lays the foundation for a potential drug therapy that might act on the same signaling pathways, to prevent epilepsy after a brain insult such as an episode of SE.”



Related Links:
Children's Hospital of Philadelphia

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Immunofluorescence Analyzer
IFA System
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.